Cullinan Therapeutics, Inc. (CGEM)
15.03
-0.42
(-2.72%)
USD |
NASDAQ |
Oct 30, 16:00
14.90
-0.13
(-0.86%)
After-Hours: 20:00
Cullinan Therapeutics Cash from Operations (Quarterly) : -38.22M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -38.22M |
| March 31, 2026 | -46.04M |
| December 31, 2025 | -38.11M |
| September 30, 2025 | -36.88M |
| June 30, 2025 | -57.61M |
| March 31, 2025 | -43.16M |
| December 31, 2024 | -36.63M |
| September 30, 2024 | -34.14M |
| June 30, 2024 | -36.29M |
| March 31, 2024 | -38.25M |
| December 31, 2023 | -18.13M |
| September 30, 2023 | -34.14M |
| June 30, 2023 | -31.01M |
| March 31, 2023 | -51.00M |
| Date | Value |
|---|---|
| December 31, 2022 | -24.98M |
| September 30, 2022 | -54.35M |
| June 30, 2022 | -25.42M |
| March 31, 2022 | -21.91M |
| December 31, 2021 | -15.17M |
| September 30, 2021 | -10.55M |
| June 30, 2021 | -16.20M |
| March 31, 2021 | -1.515M |
| December 31, 2020 | -9.436M |
| September 30, 2020 | -9.071M |
| June 30, 2020 | -6.25M |
| March 31, 2020 | -5.015M |
| December 31, 2019 | -4.869M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Climb Bio, Inc. | -10.55M |
| MapLight Therapeutics, Inc. | -44.87M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 40.68M |
| Cash from Financing (Quarterly) | 1.10M |
| Free Cash Flow | -159.26M |
| Free Cash Flow Per Share (Quarterly) | -0.6167 |
| Free Cash Flow to Equity (Quarterly) | -37.91M |
| Free Cash Flow to Firm (Quarterly) | -38.22M |
| Free Cash Flow Yield | -17.57% |